BioRestorative Therapies's revenue for the
three
months ended in Dec. 2023 was €0.02 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.14 Mil.
BioRestorative Therapies's Revenue per Share for the
three
months ended in Dec. 2023 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.03.
Warning Sign:
BioRestorative Therapies Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioRestorative Therapies was 6.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -31.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -77.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -64.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, BioRestorative Therapies's highest 3-Year average Revenue per Share Growth Rate was 80.70% per year. The lowest was -89.80% per year. And the median was -61.10% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioRestorative Therapies's Revenue
For the Biotechnology subindustry, BioRestorative Therapies's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Revenue distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Revenue falls into.
BioRestorative Therapies Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioRestorative Therapies Revenue Related Terms
Thank you for viewing the detailed overview of BioRestorative Therapies's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioRestorative Therapies (FRA:9OF) Business Description
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:9OF has been successfully added to your 